• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket

    2/5/24 8:04:43 AM ET
    $ATRA
    $BCEL
    $BETS
    $BIOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATRA alert in real time by email

    Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) rose sharply in today’s pre-market trading.

    4DMT presented interim data from randomized Phase 2 PRISM clinical trial of intravitreal 4D-150 demonstrating favorable tolerability & clinical activity in wet AMD.

    4D Molecular Therapeutics shares jumped 20.1% to $21.01 in pre-market trading

    Here are some other stocks moving in pre-market trading.

    Gainers

    • Chenghe Acquisition Co. (NASDAQ:CHEA) gained 68.1% to $9.23 in pre-market trading after dipping around 46% on Friday.
    • Tritium DCFC Limited (NASDAQ:DCFC) shares jumped 51.9% to $0.1990 in pre-market trading. Tritium DCFC said the company was the top-awarded fast charger manufacturer for the first round of the State of Tennessee’s National Electric Vehicle Infrastructure (NEVI) Formula Program.
    • YanGuFang International Group Co., Ltd. (NASDAQ:YGF) gained 27.4% to $0.7641 in pre-market trading after falling around 19% on Friday.
    • Magic Empire Global Limited (NASDAQ:MEGL) shares gained 21.6% to $0.9841 in pre-market trading.
    • CalAmp Corp. (NASDAQ:CAMP) shares gained 16.8% to $3.61 in pre-market trading after dipping around 14% on Friday. CalAmp recently announced a 1-for-23 reverse stock split.
    • 2U, Inc. (NASDAQ:TWOU) shares gained 16.1% to $ 0.9199 in pre-market trading after declining over 8% on Friday.
    • Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) shares rose 14.8% to $1.55 in pre-market trading.
    • Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares rose 14.7% to $1.40 in pre-market trading after surging 47% on Friday.
    • Griid Infrastructure Inc. (NASDAQ:GRDI) shares rose 14.4% to $2.38 in pre-market trading after dipping more than 50% on Friday.

    Losers

    • Cano Health, Inc. (NYSE:CANO) shares dipped 60% to $0.92 in pre-market trading. Cano Health initiated prearranged voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court for the District of Delaware.
    • DMK Pharmaceuticals Corporation (NASDAQ:DMK) shares fell 44.4% to $0.2889 in pre-market trading. The company filed voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware.
    • NanoString Technologies, Inc. (NASDAQ:NSTG) fell 37% to $0.2951. The company initiated a chapter 11 restructuring proceeding in the United States Bankruptcy Court for the District of Delaware.
    • Bit Brother Limited (NASDAQ:BETS) shares fell 23% to $2.31 in pre-market trading. Bit Brother received delisting notice from the Nasdaq.
    • NexImmune, Inc. (NASDAQ:NEXI) declined 12% to $11.09 in pre-market trading. NexImmune announced a $3.67 million registered direct offering priced at-the-market under Nasdaq rules.
    • SCWorx Corp. (NASDAQ:WORX) fell 10.6% to $1.10 in pre-market trading after dipping 8% on Friday.
    • Atreca, Inc. (NASDAQ:BCEL) shares declined 9.5% to $0.2489 in pre-market trading.
    • Biora Therapeutics, Inc. (NASDAQ:BIOR) shares fell 9.4% to $0.85 in pre-market trading.
    • CCSC Technology International Holdings Limited (NASDAQ:CCTG) shares dipped 8.7% to $4.72 in pre-market trading after surging 32% on Friday.
    • Banco Santander, S.A. (NYSE:SAN) shares declined 6.9% to $3.89 in pre-market trading. , Iranian entities reportedly used accounts at Lloyds Banking Group and Banco Santander to evade U.S. sanctions.

     

    Now Read This: McDonald's, Caterpillar And 3 Stocks To Watch Heading Into Monday

     

    Get the next $ATRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATRA
    $BCEL
    $BETS
    $BIOR

    CompanyDatePrice TargetRatingAnalyst
    CAMP4 Therapeutics Corporation
    $CAMP
    4/14/2026$7.00Buy
    Rodman & Renshaw
    Banco Santander S.A. Sponsored ADR (Spain)
    $SAN
    3/23/2026Equal-Weight → Overweight
    Morgan Stanley
    Banco Santander S.A. Sponsored ADR (Spain)
    $SAN
    2/23/2026Sector Perform → Outperform
    RBC Capital Mkts
    4D Molecular Therapeutics Inc.
    $FDMT
    1/28/2026$33.00Overweight
    Barclays
    Atara Biotherapeutics Inc.
    $ATRA
    1/13/2026$6.00Buy → Hold
    Canaccord Genuity
    Banco Santander S.A. Sponsored ADR (Spain)
    $SAN
    1/13/2026Hold → Buy
    Kepler
    4D Molecular Therapeutics Inc.
    $FDMT
    11/7/2025Underweight → Equal-Weight
    Morgan Stanley
    CAMP4 Therapeutics Corporation
    $CAMP
    10/2/2025$7.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ATRA
    $BCEL
    $BETS
    $BIOR
    SEC Filings

    View All

    SEC Form 424B3 filed by Banco Santander S.A. Sponsored ADR (Spain)

    424B3 - Banco Santander, S.A. (0000891478) (Filer)

    4/23/26 5:09:26 PM ET
    $SAN
    Commercial Banks
    Finance

    SEC Form 425 filed by Banco Santander S.A. Sponsored ADR (Spain)

    425 - Banco Santander, S.A. (0000891478) (Filed by)

    4/23/26 10:42:14 AM ET
    $SAN
    Commercial Banks
    Finance

    SEC Form DEFA14A filed by CAMP4 Therapeutics Corporation

    DEFA14A - Camp4 Therapeutics Corp (0001736730) (Filer)

    4/23/26 7:02:59 AM ET
    $CAMP

    $ATRA
    $BCEL
    $BETS
    $BIOR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SCWorx Announces Two New Customer Wins Through Strategic Partner Channel

    New York, NY, April 22, 2026 (GLOBE NEWSWIRE) -- SCWorx Corp. ("SCWorx" or the "Company"), a leading provider of data management, analytics, and supply chain solutions for the healthcare industry, today announced that it has secured two new customers through a strategic partner relationship. Both customers are currently engaged in preparatory data initiatives in advance of planned ERP implementations. The new engagements underscore SCWorx's growing role as a critical data readiness and normalization partner in enterprise system transformations. Each customer will leverage SCWorx's platform to standardize, cleanse, and structure key operational and financial data sets required for success

    4/22/26 10:28:56 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on April 15, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 43,000 shares of the Company's common stock to three newly hired employees of the Company, each as an inducement material to such employee's entry

    4/17/26 4:05:00 PM ET
    $CAMP

    4DMT Announces New Employment Inducement Grants

    EMERYVILLE, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on April 14, 2026, the compensation committee of the Company's board of directors granted five new non-executive employees 67,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into em

    4/17/26 4:05:00 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    $BCEL
    $BETS
    $BIOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on CAMP4 Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of CAMP4 Therapeutics with a rating of Buy and set a new price target of $7.00

    4/14/26 8:19:24 AM ET
    $CAMP

    Banco Santander upgraded by Morgan Stanley

    Morgan Stanley upgraded Banco Santander from Equal-Weight to Overweight

    3/23/26 8:22:38 AM ET
    $SAN
    Commercial Banks
    Finance

    Banco Santander upgraded by RBC Capital Mkts

    RBC Capital Mkts upgraded Banco Santander from Sector Perform to Outperform

    2/23/26 8:28:41 AM ET
    $SAN
    Commercial Banks
    Finance

    $ATRA
    $BCEL
    $BETS
    $BIOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Tardiff Daniel

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    4/3/26 4:48:21 PM ET
    $CAMP

    SEC Form 4 filed by Maricich Yuri

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    4/3/26 4:47:38 PM ET
    $CAMP

    SEC Form 4 filed by Gold Kelly

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    4/3/26 4:47:04 PM ET
    $CAMP

    $ATRA
    $BCEL
    $BETS
    $BIOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner 5am Partners Vi, Llc bought $4,499,999 worth of shares (2,941,176 units at $1.53) (SEC Form 4)

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    9/15/25 8:12:20 PM ET
    $CAMP

    Large owner Polaris Management Co. Vii, L.L.C. bought $1,999,999 worth of shares (1,307,189 units at $1.53) (SEC Form 4)

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    9/11/25 4:59:09 PM ET
    $CAMP

    Director Nashat Amir bought $1,999,999 worth of shares (1,307,189 units at $1.53) (SEC Form 4)

    4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

    9/11/25 4:48:30 PM ET
    $CAMP

    $ATRA
    $BCEL
    $BETS
    $BIOR
    Leadership Updates

    Live Leadership Updates

    View All

    CAMP4 Appoints Michael MacLean to its Board of Directors

    CAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the appointment of Michael MacLean to the Company's Board of Directors. "Mike brings an exceptional depth of financial and operational expertise built across decades of leadership at some of the most innovative biotechnology companies, and we are thrilled to welcome him to CAMP4's Board," said Josh Mandel-Brehm, Pr

    3/24/26 7:00:00 AM ET
    $CAMP

    Babcock & Wilcox Enterprises, Inc. Appoints Dr. Homaira Akbari (Ph.D.) to Board of Directors

    Babcock & Wilcox Enterprises, Inc. (B&W) (NYSE:BW) announced today that Dr. Homaira Akbari (Ph.D.) has been appointed to its Board of Directors, bringing the total to seven members. Dr. Akbari has served on the Board of Directors of over 25 public and private companies, including Veolia Group, a global leader in waste to energy, environmentals and hazardous waste facilities, and Banco Santander (NYSE:SAN). Dr. Akbari brings extensive international leadership experience across medium and large technology companies, including in the energy and finance sectors. She has held senior management roles in Fortune 1000 companies including Microsoft, Thales and Liberty Media, and served as member

    1/27/26 4:30:00 PM ET
    $BW
    $SAN
    Building Products
    Industrials
    Commercial Banks
    Finance

    Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

    PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development-stage card

    12/1/25 9:00:00 AM ET
    $CVKD
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATRA
    $BCEL
    $BETS
    $BIOR
    Financials

    Live finance-specific insights

    View All

    Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting

    PONTE VEDRA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update highlighting recent progress across its CAD-1005 program for HIT and broader 12-LOX inhibitor platform. The update reflects continued progress for CAD-1005, Cadrenal's first-in-class 12-LOX inhibitor for suspected heparin-induced thrombocytopenia (HIT), including completion of its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administra

    3/31/26 8:45:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Webster Financial Corporation Enters Into Merger Agreement With Banco Santander, S.A. for $12.3 Billion

    Creates Top Ten Retail and Commercial Bank by Assets Nationwide Establishes Top Five Bank by Deposits in the Northeast Transaction Provides Compelling Value for Webster Stockholders Webster Financial Corporation (NYSE:WBS), the holding company for Webster Bank, N.A., today announced the signing of a definitive agreement under which Banco Santander, S.A. ("Santander") (NYSE:SAN, Madrid: SAN)) will acquire Webster in a cash-and-stock transaction. Under the terms of the agreement, Webster stockholders will receive $48.75 in cash and 2.0548 Santander American Depository Shares for each Webster common share. Based on Santander's closing stock price on Monday, February 2, 2026, the trans

    2/3/26 1:38:00 PM ET
    $SAN
    $WBS
    Commercial Banks
    Finance
    Major Banks

    Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

    U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the EBVALLO™ (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one

    1/12/26 8:00:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    $BCEL
    $BETS
    $BIOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    11/26/24 5:02:01 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.

    SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)

    11/15/24 5:05:27 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care